SCHEDULE 13G: Redmile Group and Jeremy C. Green Disclose 5.1% Stake in Silence Therapeutics plc
Beneficial Ownership Report
Investment firm Redmile Group, LLC and its principal Jeremy C. Green have disclosed a beneficial ownership of 5.1% in Silence Therapeutics plc, holding over 7.1 million ordinary shares as of December 31, 2024.
Summary
- Redmile Group, LLC and Jeremy C. Green have jointly reported beneficial ownership of 7,197,951 Ordinary Shares of Silence Therapeutics plc.
- This ownership represents 5.1% of the total outstanding Ordinary Shares of Silence Therapeutics plc.
- The reported shares are held through 2,399,317 American Depositary Shares (ADSs), with each ADS representing three Ordinary Shares.
- The percentage of class is based on 141,198,163 Ordinary Shares, which was the weighted average number of shares in issue during the three months ended September 30, 2024, as reported by Silence Therapeutics plc in its Form 6-K filed on November 14, 2024.
- Both Redmile Group, LLC, as an investment manager, and Jeremy C. Green, as its principal, disclaim beneficial ownership of these shares except to the extent of their pecuniary interest.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently suggest a positive or negative sentiment regarding the company's performance or outlook. It is a factual report of an investment stake.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by a specialized healthcare investment firm in Silence Therapeutics plc, a company operating in the biotechnology and pharmaceutical sector. Such disclosures are common for institutional investors acquiring a material stake in publicly traded companies, reflecting their investment strategy rather than operational changes within the issuer.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an institutional investor like Redmile Group may be viewed positively by other shareholders as it indicates institutional confidence and liquidity in the stock.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of the three-month period for which the weighted average number of shares in issue (141,198,163) was reported by Silence Therapeutics plc in its Form 6-K. |
| 2024-11-14 | Date Silence Therapeutics plc filed its Unaudited Condensed Consolidated Interim Financial Statements (Form 6-K), which reported the weighted average number of shares in issue. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G, indicating the ownership position as of this date. |
| 2025-02-14 | Date the Schedule 13G was signed and filed by Redmile Group, LLC and Jeremy C. Green. |
Keywords
Silence Therapeutics plc, Redmile Group, Jeremy C. Green, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, American Depositary Shares, Institutional Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.